PersonGen
Latest round
- Series B
Last raised
- Jan 2026
Total raised
- Undisclosed
Investors
- 6
About PersonGen
Based in Suzhou, China, and established in 2010, PersonGen BioTherapeutics (Suzhou) Co., trading as PersonGen, is a biopharmaceuticals company that focuses on the R&D of CAR-T and other cellular immunotherapies. The company passed the ISO9001 certification. Besides, the company has won many awards, including National High-Tech Enterprise, Jiangsu Double Innovation Talent Program, and Jiangsu Province Six Talents Peak Team. The company established postdoctoral incubation workstations and Suzhou Cancer Immunotherapy Engineering Technology Research Center. The company's R&D team members are more than 80% researchers with doctoral or master's degrees. The company has applied for 30 international patents, 18 registered trademarks, and published 30 research articles in journal magazines.gov, and launched clinical trials by collaborating with more than 10 medical centers in China. The company provides cellular therapies and antibodies pipeline. Some cellular products have entered clinical trial stage, covering most hematologic malignancies and some solid tumors. The company has R&D capabilities from antigen binding domains, CAR structure optimization, CAR-T functional testing, to in vivo efficacy verification. The company has developed technology platforms, including a CAR structure and function verification platform, an in vivo efficacy verification platform, induced pluripotent stem cell (iPSC)-derived allogeneic cell therapy platform, and NanoBa bispecific antibody development platform. The company generates revenue by doing R&D and providing cellular therapeutic drugs to treat cancer and other related products.
Who invested in PersonGen
6 investors across 3 rounds
See all investors in PersonGen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about PersonGen
Who invested in PersonGen?
PersonGen has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PersonGen raised?
PersonGen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did PersonGen last raise money?
PersonGen's most recent round on record is a Series B, in Jan 2026.
What does PersonGen do?
Based in Suzhou, China, and established in 2010, PersonGen BioTherapeutics (Suzhou) Co.
Where is PersonGen headquartered?
PersonGen is headquartered in Suzhou Industrial Park, China.
Which VCs invest in companies like PersonGen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at PersonGen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like PersonGen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.